Présentation de l'entreprise
Korro Bio, Inc. operates as a biopharmaceutical entity dedicated to the discovery, development, and commercialization of genetic medicines that utilize RNA editing technologies to address rare and highly prevalent diseases within the United States. The company functions within the healthcare sector, specifically targeting the biotechnology industry, a domain characterized by high innovation potential and significant regulatory hurdles. As of the latest reporting period, Korro Bio possesses a market capitalization of $194.13M, generates annual revenue of $6.39M, and employs a workforce of 58 individuals. The relatively modest revenue figure of $6.39M in the context of a $194.13M market capitalization indicates that the company is currently in a pre-profitability stage where valuation is driven by future growth potential and intellectual property assets rather than current cash flow generation.
Santé financière
The company reports a trailing twelve-month revenue of $6.39M, which contrasts sharply with a net income loss of $-117,260,000 and an EBITDA of $-83,062,000. The substantial gap between the $6.39M revenue and the $-117,260,000 net income reveals a cost structure heavily weighted toward research and development expenses, administrative overhead, and other non-operating costs that are typical for early-stage biotechnology firms before product approval. Free cash flow stands at $-49,361,752, indicating that the company is consuming cash to fund its operations and pipeline advancement, which limits immediate financial flexibility but is a standard requirement for clinical-stage development. Gross margin is recorded at 0.0%, reflecting the accounting treatment of significant R&D costs being expensed rather than capitalized, while the operating margin of -1229.3% and profit margin of 0.0% underscore the deep losses incurred per unit of revenue generated. On the balance sheet, Korro Bio holds $75.16M in cash against $43.49M in debt, resulting in a debt-to-equity ratio of 84.54, which suggests a leveraged position where equity is relatively small compared to total debt obligations. Despite the high leverage, the current ratio of 6.90 demonstrates strong short-term liquidity, implying the company holds sufficient current assets to cover its current liabilities many times over. Furthermore, the return on equity is -110.7% and the return on assets is -32.1%, metrics that indicate management is currently utilizing shareholder capital and company assets to generate negative returns due to the burn rate associated with clinical trials and development activities.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is reported at -1.77, a metric that implies analysts do not expect immediate earnings normalization and highlights the challenges in valuing loss-making biotechnology stocks using traditional multiples. The price-to-book ratio stands at 2.46, indicating that the market values the company at a significant premium over its tangible book value, likely reflecting the high intangible value of its patent portfolio and proprietary genetic editing technologies. Alternative valuation metrics such as the price-to-sales ratio of 30.37 and an EV/EBITDA of -1.96 suggest that investors are pricing the stock based on future commercialization potential rather than current profitability or asset backing. The stock has traded within a 52-week range between a low of $5.20 and a high of $55.89, meaning the current price sits at a level that requires careful analysis of recent market sentiment to determine its position relative to this established volatility band. Additionally, the beta value of 2.43 signifies that the stock exhibits high price volatility, moving with an intensity roughly 2.43 times that of the broader market, which presents elevated risk for portfolio diversification.
Growth & Income
Revenue growth year-over-year is -43.1%, while earnings growth is marked as N/A, illustrating a period of contraction where the company is likely scaling back operations or managing costs during a specific phase of its development lifecycle. Since earnings are not growing positively and revenue is declining, the company is not in an expansionary phase of earnings generation but rather navigating a contractionary period typical for firms transitioning between clinical stages. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders but instead retains all capital to reinvest into its genetic medicine pipeline. This reinvestment strategy is essential for advancing clinical trials and securing regulatory approval for lead candidates like KRRO-121. The overall growth and income profile is characterized by negative revenue momentum, zero dividend yield, and a reliance on future product successes to reverse the current financial trajectory.